637
Participants
Start Date
September 8, 2021
Primary Completion Date
December 22, 2021
Study Completion Date
April 22, 2022
ICC Vaccine
Intramuscular (deltoid) injections of in-clinic mix of various doses of quadrivalent hemagglutinin nanoparticle influenza vaccine(qNIV2), SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant
Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
Northern Beaches Clinical Research, Brookvale
Paratus Clinical Research - Western Sydney, Blacktown
Paratus Clinical Research - Central Coast, Kanwal
Hunter Diabetes Centre, Merewether
Paratus Clinical Research - Canberra, Bruce
Emeritus Research, Camberwell
Austrials Pty Ltd - Taringa, Taringa
University of the Sunshine Coast,Southbank, Brisbane
University of the Sunshine Coast, Health Hub Morayfield, Morayfield
University of the Sunshine Coast, Sippy Downs
Lead Sponsor
Novavax
INDUSTRY